Related Experiment Video

Updated: Jun 30, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Epigallocatechin-3-gallate suppressed breast oncogenesis via the miR-27a/Wnt/β-catenin pathway axis

Shrila Banerjee1, Abul Kalam Azad Mandal1

  • 1Department of Biotechnology, School of BioSciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.

Frontiers in Oncology
|June 29, 2026
PubMed
Abstract

Insights

Epigallocatechin-3-gallate (EGCG) shows promise as a breast cancer therapy by suppressing tumor growth and metastasis. EGCG functions by modulating miR-27a-3p, impacting the Wnt/β-catenin pathway, and reducing cell proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Breast cancer presents significant global health challenges, marked by increasing chemotherapeutic side effects and chemoresistance.
  • Epigallocatechin-3-gallate (EGCG), a potent polyphenol from green tea, demonstrates notable anticancer properties, necessitating further investigation into its therapeutic mechanisms.

Purpose of the Study:

  • To investigate the tumor-suppressive effects of EGCG in breast cancer.
  • To elucidate the molecular mechanisms underlying EGCG's anticancer activity, focusing on miR-27a-3p and the Wnt/β-catenin pathway.

Main Methods:

  • Evaluated EGCG's impact on breast cancer cell viability, migration, cell cycle, and apoptosis.
  • Assessed miR-27a-3p expression levels following treatments with EGCG, a miR-27a-3p inhibitor, and their combination.
  • Examined the modulation of key Wnt/β-catenin pathway markers, including cyclin-D1, in response to EGCG treatment.

Main Results:

  • EGCG significantly reduced breast cancer cell viability and migration while inducing apoptosis and G0/G1 cell cycle arrest.
  • EGCG treatment led to decreased miR-27a-3p expression, confirming its regulatory role.
  • EGCG modulated the Wnt/β-catenin pathway, suppressing key markers like cyclin-D1, indicating a potential therapeutic route.

Conclusions:

  • EGCG exhibits significant therapeutic potential against breast cancer.
  • The anticancer effects of EGCG are mediated through the miR-27a/Wnt/β-catenin pathway.
  • EGCG holds promise for reducing breast cancer proliferation, metastasis, and relapse.
Keywords:
EGCGWnt/β-catenin pathwaybreast cancercancer therapeuticsmiR-27amicroRNA

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...